An Effectiveness Randomized Controlled Trial of Treating Moderate Tic Disorder in Children by Combining Chinese and Western Medicine

注册号:

Registration number:

ITMCTR2200006502

最近更新日期:

Date of Last Refreshed on:

2022-08-16

注册时间:

Date of Registration:

2022-08-16

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

中西药结合治疗中度儿童抽动障碍的实效性随机对照试验临床研究

Public title:

An Effectiveness Randomized Controlled Trial of Treating Moderate Tic Disorder in Children by Combining Chinese and Western Medicine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中西药结合治疗中度儿童抽动障碍的实效性随机对照试验临床研究

Scientific title:

An Effectiveness Randomized Controlled Trial of Treating Moderate Tic Disorder in Children by Combining Chinese and Western Medicine

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200062710 ; ChiMCTR2200006502

申请注册联系人:

贾茹

研究负责人:

李霁

Applicant:

Ru Jia

Study leader:

Ji Li

申请注册联系人电话:

Applicant telephone:

15101097911

研究负责人电话:

Study leader's telephone:

13911736047

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15101097911@163.com

研究负责人电子邮件:

Study leader's E-mail:

liji7978@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市西城区北线阁5号中国中医科学院广安门医院

研究负责人通讯地址:

北京市西城区北线阁5号中国中医科学院广安门医院

Applicant address:

Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beixiange No.5, Xicheng District, Beijing

Study leader's address:

Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beixiange No.5, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院广安门医院

Applicant's institution:

Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2022-145-KY

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国中医科学院广安门医院伦理委员会

Name of the ethic committee:

The Ethics Committee of Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/7/12 0:00:00

伦理委员会联系人:

乔洁

Contact Name of the ethic committee:

Jie Qiao

伦理委员会联系地址:

北京市西城区北线阁5号中国中医科学院广安门医院

Contact Address of the ethic committee:

Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beixiange No.5, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院广安门医院

Primary sponsor:

Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

北京市西城区北线阁5号中国中医科学院广安门医院

Primary sponsor's address:

Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beixiange No.5, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

具体地址:

北京市西城区北线阁5号中国中医科学院广安门医院

Institution
hospital:

Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine

Address:

Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beixiange No.5, Xicheng District, Beijing

经费或物资来源:

中国中医科学院中央公益性科研院所基本科研业务费

Source(s) of funding:

Basic Scientific Research Expenses of the Central Public Welfare Research Institute of Chinese Academy of Traditional Chinese Medicine

研究疾病:

儿童抽动障碍

研究疾病代码:

Target disease:

Tic disorder in children

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

半随机对照

Quasi-randomized controlled

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究旨在阐明5~14岁中度抽动障碍儿童的中西医结合药物疗效评价、最佳起效剂量及时间点,并提供中药、西药的安全性证据。

Objectives of Study:

The purpose of this study is to elucidate the efficacy evaluation and optimal starting dose and time point of integrated Chinese and Western medicine drugs in children aged 5 to 14 years old, and to provide the safety evidence of traditional Chinese medicine and western medicine.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)依据《精神障碍诊断与统计手册》第5版(DSM-5)标准诊断为抽动障碍、抽动秽语综合征、持续性(慢性)运动或发声抽动障碍;25≤YGTSS评分<50分。 2)中医诊断标准参照2012年中国中医药学会制定的《中医儿科常见病诊疗指南》和中国中医药出版社出版的《中医儿科学》第二版中多发性抽动症的诊断标准制定,中医辨证属:肝风内动挟痰证,主症见:努嘴张口、挤眉眨眼,摇头耸肩,全身肌肉频繁抽动,不时叫喊、声音髙亢;次症见:烦躁易怒,头晕头痛,卧睡不安,注意力不集中。舌象脉象:舌质红,苔白或微黄,脉弦滑有力。具备主症3项及以上,次症2项及以上者,结合舌象、脉象即可诊断。 3)中医证候分级量化标准参照《中医儿科临床诊疗指南·抽动障碍》。 4)年龄5~14岁; 5)符合以上诊断标准。 6)受试者及法定监护人阅读并充分理解患者须知,知情同意。

Inclusion criteria

1)Diagnosis of tic disorder, Tourette syndrome, persistent (chronic) motor or vocal tic disorder by criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 25≤ YGTSS score <50. 2)Diagnosis criteria of TCM syndrome according to the 2012 Chinese Society of Chinese Medicine and TCM Academy, TCM syndrome differentiation, complaining, frowning, blinking, shaking head, frequent muscle movements, yelling, high voice; secondary symptoms: irritability, dizziness, headache, restlessness, inattention. Tongue image pulse: red tongue, white or slightly yellow moss, smooth and strong veins. Patients with 3 or more main diseases and 2 or more secondary diseases can be diagnosed combined with tongue and pulse images. 3)The classification and quantitative standard of TCM syndrome refer to the TCM Pediatric Clinical Diagnosis and Treatment Guidelines. 4)Age is from 5 to 14 years old. 5)Meet the above diagnostic criteria. 6)The subject and the legal guardian read and fully understood the patient instructions, with informed consent.

排除标准:

1)不符合上述西医、中医诊断标准者; 2)患儿及法定监护人拒绝接受随访观察者; 3)既往有舞蹈症、手足徐动症、孤独症、肝豆状核变性、儿童精神分裂症、癫痫、药源性运动障碍、迟发性运动障碍、癔病或急性运动性障碍病史者; 4)同时服用其他精神类药物; 5)母孕及出生史异常者; 6)肝肾功能及尿常规回报明显异常者; 7)同时参与其他临床试验者。

Exclusion criteria:

1) Those who do not meet the above diagnostic standards of Western medicine and traditional Chinese medicine; 2) The child and the legal guardian refused to accept the follow-up observers; 3) Previous history of dance disorder, HFMD, autism, Wilson disease, childhood schizophrenia, epilepsy, pharmacokinetic disorder, late-onset movement disorder, hysteria or acute movement disorder; 4) Taking other psychotropic drugs at the same time; 5) Abnormal maternal pregnancy and abnormal birth history; 6) Patients with obvious abnormal liver and kidney function and urine routine returns; 7) Also participating in other clinical trials.

研究实施时间:

Study execute time:

From 2022-04-01

To      2023-04-30

征募观察对象时间:

Recruiting time:

From 2022-08-15

To      2023-04-30

干预措施:

Interventions:

组别:

中药颗粒组

样本量:

60

Group:

TCM granules

Sample size:

干预措施:

口服中药颗粒

干预措施代码:

Intervention:

Oral TCM granules

Intervention code:

组别:

硫必利+菖麻熄风片组

样本量:

60

Group:

Tiapride Hydrochioride Tablets and ChangMaXiFeng Pian

Sample size:

干预措施:

口服盐酸硫必利和菖麻熄风片

干预措施代码:

Intervention:

Oral Tiapride Hydrochioride Tablets and ChangMaXiFeng Pian

Intervention code:

组别:

硫必利组

样本量:

60

Group:

Tiapride Hydrochioride Tablets

Sample size:

干预措施:

口服盐酸硫必利片

干预措施代码:

Intervention:

Tiapride Hydrochioride Tablets

Intervention code:

样本总量 Total sample size : 180

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京市房山区良乡医院

单位级别:

三级甲等医院

Institution/hospital:

Liangxiang Hospital

Level of the institution:

Grade III A Hospital

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中日友好医院

单位级别:

三级甲等医院

Institution/hospital:

China-Japan Friendship Hospital

Level of the institution:

Grade III A Hospital

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

单位级别:

三级甲等中医医院

Institution/hospital:

Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine

Level of the institution:

Grade III A, Traditional Chinese Medicine Hospital

测量指标:

Outcomes:

指标中文名:

中医证候评分

指标类型:

次要指标

Outcome:

TCM syndrome score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件观察

指标类型:

副作用指标

Outcome:

adverse event

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

耶鲁抽动综合评分

指标类型:

主要指标

Outcome:

YGTSS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CGI-Ⅰ评分

指标类型:

次要指标

Outcome:

CGI-Ⅰ

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 5
Min age years
最大 14
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

根据患儿就诊地点随机分组,广安门医院儿科专家主任门诊为口服中药颗粒剂;广安门医院儿科普通门诊与良乡医院儿科中医门诊为口服盐酸硫必利片+菖麻熄风片;良乡医院儿科门诊及中日友好医院儿科患儿口服盐酸硫必利片。

Randomization Procedure (please state who generates the random number sequence and by what method):

The children were randomized according to their place of visit.Children presenting to the Pediatric Expert Clinic of Guang'anmen Hospital will oral TCM granules.Children who go to the Pediatric general clinic of Guang'anmen Hospital and Liangxiang Hospital pediatric traditional Chinese medicine clinic will oral Tiaprid

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用病历记录表进行数据采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data acquisition will be performed by CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above